PubMed

End-stage renal disease-associated managed care costs among patients with and without diabetes.

Joyce AT, Iacoviello JM, Nag S, Sajjan S, Jilinskaia E, Throop D, Pedan A, Ollendorf DA, Alexander CM.

Diabetes Care. 2004 Dec;27(12):2829-35.PMID: 15562193 [PubMed - indexed for MEDLINE]Related articlesFree article

Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.

Laliberté F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Piech CT, Lefebvre P.

J Manag Care Pharm. 2009 May;15(4):312-22.PMID: 19422271 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost analysis of renal replacement therapies in Finland.

Salonen T, Reina T, Oksa H, Sintonen H, Pasternack A.

Am J Kidney Dis. 2003 Dec;42(6):1228-38.PMID: 14655195 [PubMed - indexed for MEDLINE]Related articles

Incidence of ESRD and survival after renal replacement therapy in patients with type 1 diabetes: a report from the Allegheny County Registry.

Nishimura R, Dorman JS, Bosnyak Z, Tajima N, Becker DJ, Orchard TJ; Diabetes Epidemiology Research International Mortality Study; Allegheny County Registry.

Am J Kidney Dis. 2003 Jul;42(1):117-24.PMID: 12830463 [PubMed - indexed for MEDLINE]Related articles

The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland--an analysis of the RENAAL study.

Szucs TD, Sandoz MS, Keusch GW.

Swiss Med Wkly. 2004 Aug 7;134(31-32):440-7.PMID: 15389347 [PubMed - indexed for MEDLINE]Related articlesFree article

Prevalence and direct medical costs of end-stage renal disease in patients with type 2 diabetes mellitus in Switzerland for 2001.

Sandoz MS, Ess SM, Keusch GW, Schwenkglenks M, Szucs TD.

Swiss Med Wkly. 2004 Aug 7;134(31-32):448-58.PMID: 15389348 [PubMed - indexed for MEDLINE]Related articlesFree article

Current status of end-stage renal disease care in South Asia.

Jha V.

Ethn Dis. 2009 Spring;19(1 Suppl 1):S1-27-32.PMID: 19484871 [PubMed - indexed for MEDLINE]Related articles

Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.

Burgess ED, Carides GW, Gerth WC, Marentette MA, Chabot I; Canadian Hypertension Society.

Can J Cardiol. 2004 May 1;20(6):613-8.PMID: 15152291 [PubMed - indexed for MEDLINE]Related articlesFree article

Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.

Herman WH, Shahinfar S, Carides GW, Dasbach EJ, Gerth WC, Alexander CM, Cook JR, Keane WF, Brenner BM.

Diabetes Care. 2003 Mar;26(3):683-7.PMID: 12610022 [PubMed - indexed for MEDLINE]Related articlesFree article

An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.

Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Bilous RW.

J Hum Hypertens. 2004 Oct;18(10):733-8.PMID: 15116142 [PubMed - indexed for MEDLINE]Related articles

The impact of diabetes on economic costs in dialysis patients: experiences in Taiwan.

Yang WC, Hwang SJ, Chiang SS, Chen HF, Tsai ST.

Diabetes Res Clin Pract. 2001 Nov;54 Suppl 1:S47-54. Review.PMID: 11580969 [PubMed - indexed for MEDLINE]Related articles

Employer-paid nonmedical costs for patients with diabetes and end-stage renal disease.

Kamal-Bahl SJ, Pantely S, Pyenson B, Alexander CM.

Prev Chronic Dis. 2006 Jul;3(3):A83. Epub 2006 Jun 15.PMID: 16776884 [PubMed - indexed for MEDLINE]Related articlesFree article

The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.

Carides GW, Shahinfar S, Dasbach EJ, Keane WF, Gerth WC, Alexander CM, Herman WH, Brenner BM; RENAAL Investigators.

Pharmacoeconomics. 2006;24(6):549-58.PMID: 16761903 [PubMed - indexed for MEDLINE]Related articles

Pharmacoeconomic challenges in the management of diabetic nephropathy.

Rodby RA.

J Manag Care Pharm. 2004 Sep;10(5 Suppl A):S6-11.PMID: 15369419 [PubMed - indexed for MEDLINE]Related articlesFree article

Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.

Alexander CM, Lyle PA, Keane WF, Carides GW, Zhang Z, Shahinfar S.

Kidney Int Suppl. 2004 Nov;(92):S115-7. Review.PMID: 15485403 [PubMed - indexed for MEDLINE]Related articles

Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.

Seng WK, Hwang SJ, Han DC, Teong CC, Chan J, Burke TA, Carides GW, Choi YJ.

Nephrology (Carlton). 2005 Oct;10(5):520-4.PMID: 16221106 [PubMed - indexed for MEDLINE]Related articles

Economic evaluation of end stage renal disease treatment.

de Wit GA, Ramsteijn PG, de Charro FT.

Health Policy. 1998 Jun;44(3):215-32.PMID: 10182294 [PubMed - indexed for MEDLINE]Related articles

Early referral to a nephrologist is associated with better outcomes in type 2 diabetes patients with end-stage renal disease.

Frimat L, Loos-Ayav C, Panescu V, Cordebar N, Briançon S, Kessler M.

Diabetes Metab. 2004 Feb;30(1):67-74.PMID: 15029100 [PubMed - indexed for MEDLINE]Related articlesFree article

Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.

Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT.

Drugs Aging. 2006;23(12):969-76.PMID: 17154661 [PubMed - indexed for MEDLINE]Related articles

End-stage renal disease in India and Pakistan: burden of disease and management issues.

Sakhuja V, Sud K.

Kidney Int Suppl. 2003 Feb;(83):S115-8. Review.PMID: 12864888 [PubMed - indexed for MEDLINE]Related articles